减瘤性肾切除术后对同步未完全切除转移灶的观察
回顾性分析2006年以来251例同步转移性肾细胞癌患者中40例(15.9%)未完全切除低体积转移灶且多学科肿瘤委员会建议减瘤性肾切除术后观察者。中位至进展时间6个月,中位至靶向治疗时间16个月,中位总生存30个月。对进展最快病灶局部治疗或进展后继续观察可进一步推迟全身治疗。
要点
- 减瘤性肾切除术后观察的中位至靶向治疗时间为16个月。
- 11例在RECIST进展后继续观察、10例对进展最快病灶局部治疗以推迟靶向治疗。
- 中位至进展时间6个月,中位总生存30个月。
核心结论
- 同步转移性肾细胞癌未完全切除低体积转移灶患者减瘤性肾切除术后至靶向治疗时间较长。
- 对进展最快病灶局部治疗或进展后继续观察是推迟全身治疗的额外手段。
研究设计与样本
- 回顾性分析经批准的机构数据库中2006年以来251例同步转移性肾细胞癌患者,识别出40例(15.9%)未完全切除低体积转移灶且多学科肿瘤委员会建议减瘤性肾切除术后观察者。
- 40例中19例为单部位转移,21例为≥2部位转移;IMDC风险有利7例、中间24例、不良9例。
主要发现
- 中位至进展时间为6个月(范围2-30个月),中位至靶向治疗时间为16个月(范围2-43个月)。
- 11例在RECIST进展后继续观察、10例对进展最快病灶追加局部治疗以进一步推迟靶向治疗。
- 中位总生存时间为30个月(范围2-71个月)。
临床怎么用
- 作者认为,对未完全切除低体积转移灶的同步转移性肾细胞癌患者,减瘤性肾切除术后观察可使至靶向治疗时间较长。
- 作者认为,对进展最快病灶局部治疗或进展后继续观察可作为推迟全身治疗的额外手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the time-to-targeted therapy (TTT) in patients with not completely resected low-volume oligometastatic disease who were observed following debulking cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). METHODS: Patients with synchronous mRCC with not completely resected low-volume metastases and in whom observation after CN was a multidisciplinary tumor board recommendation were identified from an approved institutional database. Patient data, International Metastatic Renal Cell Cancer Database Consortium (IMDC) risk, Fuhrman grade, site, and number of sites, time-to-progression (TTP), TTT, and overall survival (OS) were retrospectively analyzed. RESULTS: From 251 synchronous mRCC patients treated since 2006, 40 (15.9 %) were identified who underwent CN with observation as a result of low-volume multiple metastasis considered not completely resectable (19 single site and 21 with ≥2 sites). IMDC risk was favorable in 7, intermediate in 24, and poor in 9 patients. Median TTP was 6 (range 2-30) months and TTT was 16 (range 2-43) months. In 11 patients targeted therapy was further deferred by observation beyond Response Evaluation Criteria in Solid Tumors progression and in 10 patients by additional local therapy of the most rapidly progressing lesion. Median OS was 30 (range 2-71) months. CONCLUSION: In patients with synchronous mRCC and not completely resected low-volume metastasis, the TTT following CN was substantial. Local therapy to control the most rapidly progressing lesion or observation beyond progression was an additional means to defer systemic therapy.
引用
- de Bruijn RE, Kuusk T, Noe AP, et al. Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. Urology. 2017. PMID: 28780300. doi:10.1016/j.urology.2017.06.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。